For Immediate Release
Contact: Berna Diehl, 202-725-2553, email@example.com
The National Pharmaceutical Council (NPC) announced that Christine Marsh, MBA, Senior Vice President, Market Access, Boehringer Ingelheim, has been elected Chair of NPC’s Board of Directors for 2023. Ms. Marsh served on NPC’s Board as Vice Chair in the previous term and has served in other board roles since 2018.
“Christine understands the varied and complex forces that impact biopharmaceutical innovation and, ultimately, the potential to improve health outcomes for patients,” said John M. O’Brien, PharmD, MPH, President and Chief Executive Officer. “As NPC continues to lead health policy research that informs critical conversations among decision-makers, it’s a privilege to have her guiding our priorities."
Ms. Marsh has been with the family-owned company since 1999, serving in roles spanning across pricing and contracts, business analytics, and managed market sales to name a few. Currently, she leads the market access team that works to ensure patients have access to Boehringer Ingelheim’s life-enhancing medicines today, tomorrow and for generations to come. This includes leading health economics & outcomes research, market access marketing/business innovation, payor sales, pricing and contracts, reimbursement, and trade specialty & distribution teams, especially in areas of unmet medical need.
As Board chair, my goals are to help decision-makers recognize the value of putting evidence to use, distinguish the value medicines provide to patients from the value extracted from medicine by supply chain incentives, attract new talent to the NPC team and mark the significance of NPC’s 70 years of work.
“Time and again, NPC’s portfolio of research has provided essential, evidence-based insights that can help decision-makers understand the value of medicines and how their decisions impact not just patient access to treatments available today, but also the development of treatments in the future,” said Marsh. “As Board chair, my goals are to help decision-makers recognize the value of putting evidence to use, distinguish the value medicines provide to patients from the value extracted from medicine by supply chain incentives, attract new talent to the NPC team and mark the significance of NPC’s 70 years of work.”
Marsh earned her Master of Business Administration from Xavier University and, early in her career, worked for companies in the business and finance sectors before pivoting into life sciences. In 2019, she earned recognition as one of the “Fiercest Women in Life Sciences” from Fierce Pharma and currently teaches management as an adjunct instructor at Sacred Heart University in Connecticut.
NPC’s Board of Directors also elected other members to its executive committee, including:
- Jennifer Norton, Vice President, U.S. Value and Access, Amgen (Vice Chair)
- Christian Nguyen, PharmD, MBA, MS, Senior Vice President, Value, Evidence and Outcomes, Eli Lilly and Company (Treasurer)
- Jim Curotto, Vice President, Integrated Account Management, Merck (Member At-Large)
- Shontelle Dodson, PharmD, Executive Vice President, Medical Affairs Head, Astellas (Member At-Large)
In addition to the executive committee, the Board of Directors made appointments to two standing Board-level committees. Jan E. Hansen, PhD, Vice President of the Evidence for Access Medical Unit, U.S. Medical Affairs, Genentech Inc., will continue to serve as chair of the Research Committee. In addition to her role as Treasurer, Dr. Nguyen will serve another term as the Chair of the Strategic Advisory Group.
“As our organization heads into its 70th year, the talent and expertise represented among our board members uniquely positions us to deliver quality research that answers our most pressing health policy questions,” said O’Brien. “And, as the number of women in leadership positions within our member companies continues to grow, I’m proud that the NPC board reflects the vital contributions that women in biopharma make each day.”
About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.